Donanemab and another new drug for Alzheimer’s called Lecanemab have been billed as a huge step forward in research ...

Diagnosed with mild cognitive impairment (MCI) in 2018, Mr Almond, from Esher, took part in two 18-month trials for donanemab ...

Donanemab: Everything we know about the latest Alzheimer’s drug rejected by the NHS - Donanemab and another new drug for ...

The National Institute for Health and Care Excellence (NICE) has rejected the Alzheimer’s drug donanemab because the ...

Eli Lilly's donanemab receives UK approval for mild cognitive impairment and mild dementia due to Alzheimer's disease.

If I were a statistician tucked away in an NHS backroom, I might well curse the day the health service was founded. There, on ...

Donanemab, the most effective treatment yet for the disease, has been banned on the health service despite regulators ...

The Alzheimer's Society Cymru has responded to the approval of a new Alzheimer's treatment. The Medicines and Healthcare ...

A retired journalist who took part in the clinical trial for the new Alzheimer’s drug has described how he feels “as normal ...

Donanemab marks a significant advancement in Alzheimer’s treatment, but NHS patients face a setback with NICE's rejection of ...

The UK’s National Institute of Health and Care Excellence (NICE) said the drug provided only a small benefit to patients.

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved US pharma major Eli Lilly’s Kisunla (donanemab ...